Dataset Information


IAP antagonists induce anti-tumor immunity in multiple myeloma.

ABSTRACT: The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-?B pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.


PROVIDER: S-EPMC5515246 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4090267 | BioStudies
1000-01-01 | S-EPMC5675670 | BioStudies
2006-01-01 | S-EPMC1626104 | BioStudies
2018-01-01 | S-EPMC6076221 | BioStudies
2019-01-01 | S-EPMC6407248 | BioStudies
2018-01-01 | S-EPMC5843221 | BioStudies
1000-01-01 | S-EPMC5832869 | BioStudies
2020-01-01 | S-EPMC7188921 | BioStudies
2019-01-01 | S-EPMC6610055 | BioStudies
1000-01-01 | S-EPMC4884961 | BioStudies